Page last updated: 2024-11-04

gatifloxacin and Heart Septal Defects, Ventricular

gatifloxacin has been researched along with Heart Septal Defects, Ventricular in 1 studies

Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.

Heart Septal Defects, Ventricular: Developmental abnormalities in any portion of the VENTRICULAR SEPTUM resulting in abnormal communications between the two lower chambers of the heart. Classification of ventricular septal defects is based on location of the communication, such as perimembranous, inlet, outlet (infundibular), central muscular, marginal muscular, or apical muscular defect.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brogan, SE1
Cahalan, MK1

Other Studies

1 other study available for gatifloxacin and Heart Septal Defects, Ventricular

ArticleYear
Gatifloxacin as a possible cause of serious postoperative hypoglycemia.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:3

    Topics: Anti-Infective Agents; Blood Glucose; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary

2005